We serve Chemical Name:2-thien-3-ylacetohydrazide CAS:175276-94-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-thien-3-ylacetohydrazide
CAS.NO:175276-94-5
Synonyms:2-(3-thienyl)ethanohydrazide;3-Thiopheneacetic acid, hydrazide;[3]Thienyl-essigsaeure-hydrazid;[3]thienyl-acetic acid hydrazide;MFCD00052946;thiophen-3-ylacetic acid hydrazide;2-(3-Thienyl)acetohydrazide;2-thien-3-ylacetohydrazide;thiophene-3-acetic hydrazide;2-(Thien-3-yl)acetohydrazide;Thiophene-3-acetic acid hydrazide
Molecular Formula:C6H8N2OS
Molecular Weight:156.206
HS Code:2934999090
Physical and Chemical Properties:
Melting point:85-86°C
Boiling point:387.5±25.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.597
PSA:83.36000
Exact Mass:156.035736
LogP:-0.18
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-(3-thienyl)ethanohydrazide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Thiophene-3-acetic acid hydrazide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(3-thienyl)ethanohydrazide Use and application,2-(Thien-3-yl)acetohydrazide technical grade,usp/ep/jp grade.
Related News: Earlier this year, the US Food and Drug Administration approved Verquvo to reduce the risk of cardiovascular death and heart failure hospitalisation, following a hospitalisation for heart failure or need for outpatients intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%. N-Acetyl-N-methylnitrosoradikal manufacturers A major advantage of identifying suitable biocatalysts early on is that it provides ample opportunity for optimization. 6-diethylcarbamoyl-1-ethyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid suppliers Expedite biocatalysis development by partnering with an API CDMO 3-phenyl-1-vinyloxybut-2-ene vendor & factory Earlier this year, the US Food and Drug Administration approved Verquvo to reduce the risk of cardiovascular death and heart failure hospitalisation, following a hospitalisation for heart failure or need for outpatients intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.,Expedite biocatalysis development by partnering with an API CDMO
